Beruflich Dokumente
Kultur Dokumente
Type
Public
Traded as
BSE: 500257
NSE: LUPIN
Industry
Pharmaceuticals
Founded
1968
Founder(s)
Headquarters
COMPANYs FINANCIALS
Mar ' 14
Mar ' 13
Mar ' 12
Mar ' 11
Mar '
Total revenue
9,430.97
7,328.26
5,388.32
4,511.46
3,673.
2,324.22
1,260.43
671.84
809.47
647.85
51.84
28.16
18.01
18.15
INDUSTRY OVERVIEW
Demand from the exports market has been growing rapidly due to the
capability of Indian players to produce cost-effective drugs with world
72.96
Hospitals & other health care organizations buy in bulk quantities and
exert pressure on pharmaceutical companies to keep prices in check
Regular patients have lost bargaining power due to price increases in
generic drugs
The bargaining power of buyers is a MEDIUM competitive force
Pharma industry can switch from their suppliers without incurring a very
high cost.
Barriers to Entry
High entry barriers due to costs associated with research & development
of new drugs (i.e. years of investment in R&D for a drug that may/may not
work)
Government regulation
Threat of Substitutes
Demand for generic versus brand name drugs has increased because of
the costs
Generic drug companies do not have the high costs associated with the
research & development of new drugs and that allows them to sell at
cheaper prices
Industry Competition
Top player in the country has only 6% market share and the next five have
18%.